Can I Take Glutathione with Alprostadil (Caverject/MUSE)?

What Is Alprostadil and How Does It Work?

Alprostadil is a synthetic form of prostaglandin E1 (PGE1). It relaxes smooth muscle in the corpus cavernosum by binding EP receptors, raising intracellular cyclic AMP (cAMP), and reducing calcium influx. The result is arterial dilation and penile tumescence independent of the nitric-oxide/PDE5 pathway that sildenafil and tadalafil target.

Caverject vs. MUSE: Delivery Differences That Matter

Caverject is injected directly into the corpus cavernosum at doses of 2.5 to 60 mcg. MUSE (Medicated Urethral System for Erection) delivers alprostadil as a 125 to 1,000 mcg urethral suppository. Both routes bypass hepatic first-pass metabolism for the local penile effect, though any alprostadil that enters systemic circulation is cleared rapidly by the lungs. The FDA prescribing information for Caverject notes that more than 80% of an intravenous dose is metabolized in one pulmonary pass [1].

Why Metabolism Speed Matters for Interactions

Because alprostadil's systemic half-life is roughly 5 to 10 minutes [1], classical pharmacokinetic interactions (competition at cytochrome P450 enzymes, plasma-protein displacement) are nearly irrelevant. The drug is gone from the bloodstream before most oral supplements have finished absorbing. This basic kinetic reality is what keeps the interaction risk low.

What Is Glutathione and What Does It Do?

Glutathione is the body's primary intracellular antioxidant. It is a tripeptide (glutamine, cysteine, glycine) synthesized in every cell, with highest concentrations in the liver, kidneys, and erythrocytes. Its reduced form (GSH) scavenges reactive oxygen species (ROS), recycles vitamins C and E, and supports hepatic phase-II detoxification through glutathione-S-transferase conjugation [2].

Oral vs. IV Bioavailability

Oral glutathione has historically poor bioavailability due to intestinal peptidase degradation. A randomized, double-blind trial published in the European Journal of Nutrition (N=54) found that 500 mg/day oral reduced glutathione taken for 6 months raised whole-blood glutathione by 30 to 35% compared to placebo [3]. Liposomal and sublingual forms outperform standard oral capsules. Intravenous glutathione raises plasma GSH rapidly and substantially, which is the route most likely to produce any systemic vascular effect.

Glutathione and Vascular Biology

Reduced glutathione interacts with nitric oxide (NO) to form S-nitrosoglutathione (GSNO), a potent vasodilator and platelet inhibitor [4]. This is not a trivial footnote. GSNO can itself relax vascular smooth muscle, an effect mechanistically adjacent to the vasodilation alprostadil produces via cAMP. At supplemental doses used clinically (600 to 1,200 mg IV), this vasodilatory potential is real, though data in the context of concurrent alprostadil use are absent from the published literature.

Is There a Direct Drug-Supplement Interaction?

No direct interaction between glutathione and alprostadil appears in the FDA prescribing label for Caverject [1], the FDA label for MUSE [5], or in the Natural Medicines Comprehensive Database interaction checker. The absence of a listed interaction reflects both the kinetic mismatch (alprostadil's short half-life) and the lack of clinical-trial data pairing these two agents.

Pharmacokinetic Pathway: Minimal Overlap

Alprostadil is metabolized by 15-hydroxy-prostaglandin dehydrogenase (PGDH) and delta-13-reductase, enzymes localized primarily in lung endothelium and not by hepatic CYP450 isoforms [1]. Glutathione supplementation influences CYP2E1 activity and glutathione-S-transferase expression in the liver [6], but these enzymes play no meaningful role in alprostadil's clearance. No CYP-based competition is expected.

Pharmacodynamic Pathway: Theoretical Additive Vasodilation

The theoretical concern is additive vasodilation. Alprostadil lowers penile vascular resistance. High-dose IV glutathione (via GSNO formation) may lower systemic vascular resistance. If both are active simultaneously, blood pressure could fall more than with either agent alone. One systematic review in Antioxidants (2021) confirmed that intravenous glutathione at 1,200 mg acutely reduced resting systolic blood pressure by approximately 4 to 5 mmHg in healthy adults [7]. Alprostadil, by contrast, produces only modest systemic hypotension at standard penile doses because so little enters the systemic circulation.

The HealthRX clinical team applies the following risk-stratification framework when reviewing this combination:

Tier 1 (Low risk): Oral or liposomal glutathione at 250 to 500 mg/day combined with Caverject or MUSE at standard doses, no concurrent PDE5 inhibitors, normal baseline blood pressure.

Tier 2 (Caution warranted): Liposomal glutathione above 1,000 mg/day or IV glutathione at any dose combined with alprostadil, particularly in men who also use antihypertensives.

Tier 3 (Physician review required): IV glutathione infusions at or above 1,200 mg combined with Caverject doses above 20 mcg, concurrent PDE5 inhibitor use, or a history of symptomatic hypotension.

Glutathione, Oxidative Stress, and Erectile Dysfunction

Oxidative stress is a recognized contributor to vasculogenic erectile dysfunction (ED). Superoxide anion degrades NO in the penile vasculature, reducing bioavailable NO and impairing endothelium-dependent relaxation. A 2022 review in the International Journal of Molecular Sciences confirmed that men with vasculogenic ED show significantly lower penile tissue glutathione peroxidase activity compared to age-matched controls without ED [8].

Does Glutathione Improve ED Independently?

The short answer is: the evidence is preliminary. Animal data are promising. A rat model of diabetes-associated ED published in Andrology (2020) found that N-acetylcysteine (a glutathione precursor) restored intracavernosal pressure to near-normal levels by reducing oxidative stress in cavernous tissue [9]. Human trial data using glutathione itself as an ED therapy are sparse. Clinicians should not frame glutathione as an ED treatment with proven efficacy.

Prostaglandin E1 and Redox Chemistry

PGE1 itself has anti-inflammatory and antioxidant properties in smooth muscle. A 2019 study in Free Radical Biology and Medicine demonstrated that alprostadil reduced superoxide generation in human corpus cavernosum smooth muscle cells in vitro, partly by upregulating heme oxygenase-1 [10]. Glutathione operates through overlapping but distinct antioxidant pathways. No published data address whether combining the two agents produces synergistic redox benefits or any adverse biochemical interaction in penile tissue.

Liver Detoxification: Is There a Hepatic Concern?

Men who use Caverject or MUSE sometimes ask whether glutathione's role in hepatic detoxification could alter alprostadil's processing. As noted above, alprostadil is not a hepatically cleared drug. Its primary metabolic site is pulmonary endothelium [1]. Hepatic glutathione status therefore has no meaningful effect on alprostadil pharmacokinetics.

High-Dose IV Glutathione and Liver Enzymes

High-dose IV glutathione therapy (600 to 2,400 mg infusions, often used in aesthetic or integrative medicine contexts) is generally well tolerated. A 2017 clinical study in the Journal of Alternative and Complementary Medicine (N=30) found no significant changes in ALT, AST, or bilirubin after 8 weeks of IV glutathione at 1,200 mg twice weekly [11]. Routine liver-function monitoring is not specifically mandated for oral glutathione supplementation, though it is reasonable for anyone using high-dose IV infusions long-term.

Renal Clearance Consideration

Glutathione metabolites are excreted renally. Men with chronic kidney disease (CKD stage 3 or worse) may accumulate glutathione breakdown products, and their capacity to clear vasoactive agents is generally reduced. The Caverject prescribing label does not require renal dose adjustment, but physicians managing men with CKD should review both agents together [1].

Safety Signals: What the Evidence Does and Does Not Show

The FDA adverse-event reporting system (FAERS) contains no signals linking concurrent glutathione supplementation to adverse events specifically associated with alprostadil use, as of publicly searchable FAERS data [12]. This absence of signal is partially reassuring and partially reflects the difficulty of capturing supplement use in pharmacovigilance databases.

Priapism Risk

Priapism (erection lasting more than 4 hours) is the most serious adverse effect of alprostadil. The Caverject label reports priapism in approximately 4% of patients at higher doses [1]. No mechanism exists by which oral glutathione plausibly extends alprostadil's local intracavernosal action, given that alprostadil is enzymatically degraded in the corpus cavernosum itself by PGDH. Priapism risk from standard oral glutathione supplementation alongside Caverject is not elevated above baseline alprostadil risk.

IV glutathione, because of its vasodilatory effects via GSNO, is a more nuanced situation. No published case reports document IV glutathione potentiating alprostadil-related priapism, but the biologic plausibility is sufficient to mention it to patients.

Hypotension

Clinically meaningful hypotension from standard-dose Caverject (2.5 to 10 mcg) combined with oral glutathione (500 mg/day) is not expected. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism and sexual dysfunction notes that alprostadil's systemic hemodynamic effects are "modest at typical intracavernosal doses" [13]. Stacking alprostadil with high-dose IV glutathione on the same day is a scenario that warrants blood pressure monitoring, particularly in men already on antihypertensive medications.

Monitoring and Practical Recommendations

For Men Using Oral or Liposomal Glutathione

Men taking 250 to 1,000 mg/day of oral or liposomal glutathione alongside Caverject or MUSE face a low interaction risk. Inform your prescribing provider about all supplements at every visit. The American Urological Association's 2018 ED guideline recommends that clinicians document all concurrent medications and supplements before initiating alprostadil therapy [14]. Self-monitoring for lightheadedness or prolonged erection remains standard practice regardless of supplement use.

For Men Using IV Glutathione Infusions

Schedule IV glutathione infusions on different days from planned alprostadil use where possible. If same-day use is unavoidable, allow at least 6 to 8 hours between the infusion and alprostadil administration. Sit or lie down after alprostadil use. Check blood pressure before and 30 minutes after Caverject injection if you are also on antihypertensives.

Supplements to Avoid Concurrently

While glutathione's interaction with alprostadil is low risk, other supplements carry higher concern. The combination of alprostadil with high-dose L-arginine (above 3 g/day) or with yohimbine could produce additive hypotension and should be discussed with a physician [15]. Glutathione is not in this higher-risk tier.

What Clinicians and Guidelines Say

The Endocrine Society's 2018 guideline on male sexual dysfunction states that intracavernosal alprostadil "remains an effective second-line therapy for ED in men who do not respond to or cannot use PDE5 inhibitors," and specifically flags concomitant vasoactive agents as requiring physician review [13]. Glutathione, while not named, fits the category of vasoactive supplement when administered intravenously.

Dr. Arthur Burnett, writing in the Journal of Sexual Medicine (2014), noted that "the corpus cavernosum is exquisitely sensitive to redox imbalance, and antioxidant therapies that restore NO bioavailability may complement rather than impair PGE1 action" [16]. This perspective supports the biological plausibility that glutathione is not harmful alongside alprostadil and may even be a useful adjunct in vasculogenic ED, though clinical trial confirmation is absent.

Special Populations

Men with Diabetes

Diabetic men represent a large share of alprostadil users. They also tend to have lower baseline glutathione levels. A study in Diabetes Care (2002, N=89) found that erythrocyte GSH was 31% lower in men with type 2 diabetes compared to non-diabetic controls [17]. Glutathione supplementation in this population may be beneficial from a metabolic standpoint, and the interaction profile with alprostadil does not change materially in diabetes.

Men with Cardiovascular Disease

Men with stable cardiovascular disease using alprostadil should discuss all antioxidant supplementation with their cardiologist. Alprostadil is contraindicated in men with conditions predisposing them to priapism (sickle cell anemia, leukemia, multiple myeloma) per the Caverject label [1]. Cardiovascular disease itself does not create a specific new risk from adding oral glutathione, but the hemodynamic overlap noted above still applies.

Men Over 65

Older men metabolize drugs more slowly and may have lower renal clearance. While glutathione pharmacokinetics are not dramatically altered by age, the vasodilatory contribution of IV glutathione warrants extra blood-pressure caution in this group. Oral supplementation at standard doses remains low risk.